Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Assets Average (2016 - 2025)

Historic Assets Average for Protalix BioTherapeutics (PLX) over the last 16 years, with Q3 2025 value amounting to $80.4 million.

  • Protalix BioTherapeutics' Assets Average rose 499.47% to $80.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $80.4 million, marking a year-over-year increase of 499.47%. This contributed to the annual value of $78.9 million for FY2024, which is 1257.3% up from last year.
  • According to the latest figures from Q3 2025, Protalix BioTherapeutics' Assets Average is $80.4 million, which was up 499.47% from $76.2 million recorded in Q2 2025.
  • In the past 5 years, Protalix BioTherapeutics' Assets Average registered a high of $105.5 million during Q2 2021, and its lowest value of $56.2 million during Q4 2022.
  • Moreover, its 5-year median value for Assets Average was $77.5 million (2023), whereas its average is $77.9 million.
  • As far as peak fluctuations go, Protalix BioTherapeutics' Assets Average crashed by 3884.67% in 2022, and later surged by 5289.7% in 2023.
  • Quarter analysis of 5 years shows Protalix BioTherapeutics' Assets Average stood at $78.6 million in 2021, then fell by 28.41% to $56.2 million in 2022, then skyrocketed by 52.9% to $86.0 million in 2023, then dropped by 21.52% to $67.5 million in 2024, then increased by 19.09% to $80.4 million in 2025.
  • Its Assets Average was $80.4 million in Q3 2025, compared to $76.2 million in Q2 2025 and $73.7 million in Q1 2025.